Corresponding Author: Christine M. Albert, MD, MPH, Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, 127 S San Vincente Blvd, AHSP 3100, Los Angeles, CA 90048 (christine.albert@cshs.org).
Accepted for Publication: January 30, 2021.
Author Contributions: Dr Albert had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Albert, Danik, Mora, Manson.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Albert, Danik.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Cook, Moorthy.
Obtained funding: Albert, Manson.
Administrative, technical, or material support: Albert, Pester, Ridge, Ng, Mora, Manson.
Supervision: Albert, Danik, Manson.
Conflict of Interest Disclosures: Dr Albert reported receipt of grants from St Jude Medical, Abbott, and Roche Diagnostics. Dr Mora reported serving as a consultant to Quest Diagnostics and Pfizer and receipt of grants from Atherotech Diagnostics. Dr Buring reported that her spouse is on the scientific advisory board of Pharmavite LLC, which provided the vitamin D/placebo for this trial. Dr Manson reported receiving grants from Mars Symbioscience. No other disclosures were reported.
Funding/Support: The VITAL Rhythm Study was supported by grant R01HL116690 from the National Heart, Lung, and Blood Institute and the VITAL trial was supported by grants U01 CA138962 and R01 CA138962, which included support from the National Cancer Institute, National Heart, Lung and Blood Institute, Office of Dietary Supplements, National Institute of Neurological Disorders and Stroke, and National Center for Complementary and Integrative Health. Pharmavite LLC (vitamin D3) and Pronova BioPharma/BASF (omega-3 fatty acids) donated the study agents, matching placebos, and packaging. Quest Diagnostics performed the serum 25-hydroxyvitamin D and plasma phospholipid omega-3 measurements at no additional cost. Dr Siddiqi was supported by grant HL007575 from the National Heart, Lung, and Blood Institute. Dr Mora was supported by grant DK112940 from the National Institute of Diabetes and Digestive and Kidney Diseases and grants R01HL134811 and K24 HL136852 from the National Heart, Lung, and Blood Institute.
Role of the Funder/Sponsor: The NIH, the sponsors of the VITAL trial, participated in discussions in the design and conduct of the parent VITAL trial but not in the VITAL Rhythm Study. The NIH did not participate in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. The other funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Group Information: A list of the members of the VITAL Research Group is included in Supplement 3.
Disclaimer: The opinions expressed in the article are those of the study authors.
Meeting Presentation: Portions of this study were presented at the American Heart Association 2020 Annual Scientific Sessions Meeting; November 13, 2020; Dallas, Texas (virtual).
Data Sharing Statement: See Supplement 4.
Additional Contributions: We acknowledge the invaluable contributions and dedication of the 25 871 participants in VITAL and the entire staff of the VITAL trial and the VITAL Rhythm Study. In particular, we acknowledge Jennie Lytel-Sternberg, BA, Ashley Lawrence, BSN, RN, and Lindsay Ventura, BS, of the Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, who collected data for the AF end point, and Min Wu, MPH, and Matthew Driver, MPH, of the Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, for editorial assistance with the tables and figures, all of whom were compensated for their efforts.
3.Odutayo
A , Wong
CX , Hsiao
AJ , Hopewell
S , Altman
DG , Emdin
CA . Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.
BMJ. 2016;354:i4482. doi:
10.1136/bmj.i4482PubMedGoogle ScholarCrossref 9.Brouwer
IA , Heeringa
J , Geleijnse
JM , Zock
PL , Witteman
JC . Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation: the Rotterdam Study.
Am Heart J. 2006;151(4):857-862. doi:
10.1016/j.ahj.2005.07.029PubMedGoogle ScholarCrossref 11.Mariani
J , Doval
HC , Nul
D ,
et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials.
J Am Heart Assoc. 2013;2(1):e005033. doi:
10.1161/JAHA.112.005033PubMedGoogle Scholar 13.Nicholls
SJ , Lincoff
AM , Garcia
M ,
et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.
JAMA. 2020;324(22):2268-2280. doi:
10.1001/jama.2020.22258PubMedGoogle ScholarCrossref 17.Luttmann-Gibson
H , Mora
S , Camargo
CA ,
et al. Serum 25-hydroxyvitamin D in the Vitamin D and Omega-3 Trial (VITAL): clinical and demographic characteristics associated with baseline and change with randomized vitamin D treatment.
Contemp Clin Trials. 2019;87:105854. doi:
10.1016/j.cct.2019.105854PubMedGoogle Scholar 18.January
CT , Wann
LS , Alpert
JS ,
et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol. 2014;64(21):e1-e76. doi:
10.1016/j.jacc.2014.03.022PubMedGoogle ScholarCrossref 19.Kirchhof
P , Benussi
S , Kotecha
D ,
et al; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J. 2016;37(38):2893-2962. doi:
10.1093/eurheartj/ehw210PubMedGoogle ScholarCrossref 21.London
B , Albert
C , Anderson
ME ,
et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and Their Role in Cardiac Arrhythmogenesis Workshop.
Circulation. 2007;116(10):e320-e335. doi:
10.1161/CIRCULATIONAHA.107.712984PubMedGoogle ScholarCrossref 26.Kumar
S , Sutherland
F , Morton
JB ,
et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion.
Heart Rhythm. 2012;9(4):483-491. doi:
10.1016/j.hrthm.2011.11.034PubMedGoogle ScholarCrossref 27.Bianconi
L , Calò
L , Mennuni
M ,
et al. n-3 Polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
Europace. 2011;13(2):174-181. doi:
10.1093/europace/euq386PubMedGoogle ScholarCrossref 28.Kowey
PR , Reiffel
JA , Ellenbogen
KA , Naccarelli
GV , Pratt
CM . Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
JAMA. 2010;304(21):2363-2372. doi:
10.1001/jama.2010.1735PubMedGoogle ScholarCrossref 30.Mayyas
F , Sakurai
S , Ram
R ,
et al. Dietary ω3 fatty acids modulate the substrate for post-operative atrial fibrillation in a canine cardiac surgery model.
Cardiovasc Res. 2011;89(4):852-861. doi:
10.1093/cvr/cvq380PubMedGoogle ScholarCrossref 32.Siscovick
DS , Barringer
TA , Fretts
AM ,
et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association.
Circulation. 2017;135(15):e867-e884. doi:
10.1161/CIR.0000000000000482PubMedGoogle ScholarCrossref 39.Jonas
DE , Kahwati
LC , Yun
JDY , Middleton
JC , Coker-Schwimmer
M , Asher
GN . Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force.
JAMA. 2018;320(5):485-498. doi:
10.1001/jama.2018.4190PubMedGoogle ScholarCrossref